Cell Source, Inc.

CLCS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023
Assets
Cash & Equivalents $1.2K $74.6K $23.0K $90.5K $23 $22.2K $2.6K $22.0K
Accounts Receivable — — — — — — — —
Inventory — — — — — — — —
Total Current Assets — — — — — — — —
Property, Plant & Equipment — — — — — — — —
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $292.4K $286.5K $264.7K $429.8K $82.6K $195.2K $248.4K $362.3K
Liabilities
Accounts Payable $1.9M $1.9M $2.0M $1.8M $1.9M $1.5M $1.6M $927.8K
Total Current Liabilities — — — — — — — —
Long-Term Debt — — — — — — — —
Total Liabilities $20.4M $18.8M $19.2M $17.7M $16.8M $15.8M $16.3M $15.3M
Stockholders' Equity
Retained Earnings $-47.7M $-46.2M $-45.8M $-44.4M $-42.9M $-41.7M $-40.6M $-39.3M
Total Stockholders' Equity $-20.1M $-18.5M $-18.9M $-17.3M $-16.8M $-15.6M $-16.0M $-14.9M
← Newer Page 1 of 6 Older →